# Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

> **NCT06074757** · PHASE1 · COMPLETED · sponsor: **Kashiv BioSciences, LLC** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant injection

## Key facts

- **NCT ID:** NCT06074757
- **Lead sponsor:** Kashiv BioSciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2023-09-10
- **Final completion:** 2023-10-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06074757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06074757, "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06074757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*